<DOC>
	<DOCNO>NCT02560363</DOCNO>
	<brief_summary>This open-label , randomize , cross single oral dose study compare pharmacokinetics different formulation AZD9977 Part A influence food Part B healthy male subject</brief_summary>
	<brief_title>A Study Compare Pharmacokinetics Different Formulations AZD9977 Influence Food Healthy Male Subjects</brief_title>
	<detailed_description>This open-label , randomize , cross single oral dose study compare pharmacokinetics three different extended-release formulation immediate-release formulation ( reference ) AZD9977 Part A influence food Part B healthy male subject</detailed_description>
	<criteria>Provision sign date , write informed consent prior study specific procedure . Healthy male subject age 18 50 year suitable vein cannulation repeat venipuncture . Male subject comply restriction sexual activity provide . Have body mass index ( BMI ) 18 32 kg/m2 , inclusive , weigh least 50 kg . Subject judge likely complete agree eat specify highfat , highcalorie standardize FDA breakfast . Able understand , read speak English language . History clinically significant disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism excretion drug . Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration IMP . Any clinically significant abnormality clinical chemistry , hematology urinalysis result , judged investigator . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) antibody . Abnormal finding vital sign , 10 minute rest supine position , define follow : Systolic blood pressure ( SBP ) &lt; 90 mmHg ≥ 140 mmHg Diastolic blood pressure ( DBP ) &lt; 50 mmHg ≥ 90 mmHg Pulse &lt; 45 &gt; 90 bpm Any clinically important abnormality rhythm , conduction morphology electrocardiogram ( ECG ) screen predose , consider investigator . Prolonged QTcF &gt; 450 m family history long QT syndrome . PR ( PQ ) interval shorten &lt; 120 m ( PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation ) . PR ( PQ ) interval prolongation &gt; 240 m ; intermittent second ( history Wenckebach block asleep exclusive ) third degree atrioventricular ( AV ) block AV dissociation . Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) intraventricular conduction delay ( IVCD ) QRS &gt; 110 m . Subjects QRS &gt; 110 m &lt; 115 m acceptable evidence ventricular hypertrophy preexcitation . Serum potassium high 5.0 mmol/L screen admission study center ( Day 1 ) . Known suspected history drug abuse , judge investigator . Current smoker smoke used nicotine product within 3 month prior screen . History alcohol abuse excessive intake alcohol judge investigator . Positive screen drug abuse , alcohol cotinine screen admission study center . History severe allergy/hypersensitivity ongoing clinically important allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD9977 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea chocolate ) judge investigator . Use drug enzyme induce property St John 's Wort within 3 week prior first dose AZD9977 . Use prescribe nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior 1st dose Part A , long medication long halflife . Plasma donation within 1 month screen blood donation/loss 500 mL 3 month prior screen . Has receive another new chemical entity ( define compound approve marketing ) within 3 month first administration IMP study . The period exclusion begin 3 month final dose 1 month last visit whichever long . Subjects previously receive AZD9977 Involvement AstraZeneca , PAREXEL , study site employee close relative . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . Subjects vegan , vegetarian medical dietary restriction . Subjects communicate reliably investigator . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>AZD9977</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Food effect</keyword>
	<keyword>AZD9977 capsule</keyword>
	<keyword>AZD9977 suspension</keyword>
</DOC>